Stockreport

Acrivon Therapeutics Highlights its Powerful Generative Phosphoproteomics AP3 Platform with Compelling Preclinical Data for ACR-2316 with Three Presentations at the Upcoming AACR-NCI-EORTC...

Acrivon Therapeutics, Inc.  (ACRV) 
PDF Favorable ACR-2316 preclinical data, demonstrating its differentiated and superior pathway effects versus benchmark WEE1 and PKMYT1 inhibitors consistent with prior obs [Read more]